Denis Horgan explains the importance of actively engaging policy makers in PIONEER

Denis Horgan - Executive Director, European Alliance for Personalised Medicine
Denis Horgan explains the importance of actively engaging policy makers in PIONEER ( Denis Horgan - Executive Director, European Alliance for Personalised Medicine )
13 May 2019

Dr Billy Franks explains the importance of data analysis plans for PIONEER’s research questions

Dr Billy Franks - Astellas Pharma B.V.
Dr Billy Franks explains the importance of data analysis plans for PIONEER’s research questions ( Dr Billy Franks - Astellas Pharma B.V. )
13 May 2019

Prof Anders Bjartell discusses the data sources and access of the PIONEER data models

Prof Anders Bjartell - Skåne University Hospital, Malmö, Lund University, Sweden
Prof Anders Bjartell discusses the data sources and access of the PIONEER data models ( Prof Anders Bjartell - Skåne University Hospital, Malmö, Lund University, Sweden )
13 May 2019

Dr Alex Asiimwe, EFPIA lead for PIONEER, discusses the unique public-private aspects of BD4BO

Dr Alex Asiimwe - Director, BAYER AG, Medical affairs, Epidemiology
Dr Alex Asiimwe, EFPIA lead for PIONEER, discusses the unique public-private aspects of BD4BO ( Dr Alex Asiimwe - Director, BAYER AG, Medical affairs, Epidemiology )
13 May 2019

Controversies in the management of prostate cancer

Prof Mach Roach III - University of California, San Francisco, USA
Controversies in the management of prostate cancer ( Prof Mach Roach III - University of California, San Francisco, USA )
9 May 2019

Local treatment in oligometastatic prostate cancer: Radiotherapy

Prof Mach Roach III - University of California, San Francisco, USA
Local treatment in oligometastatic prostate cancer: Radiotherapy ( Prof Mach Roach III - University of California, San Francisco, USA )
9 May 2019

SBRT photons, protons or carbon for prostate cancer: How good is the data?

Prof Mach Roach III - University of California, San Francisco, USA
SBRT photons, protons or carbon for prostate cancer: How good is the data? ( Prof Mach Roach III - University of California, San Francisco, USA )
9 May 2019

Differences in hormone therapy for patients with advanced metastatic prostate cancer

Prof Axel Merseburger - University Hospital Schleswig-Holstein, Lübeck, Germany
Differences in hormone therapy for patients with advanced metastatic prostate cancer ( Prof Axel Merseburger - University Hospital Schleswig-Holstein, Lübeck, Germany )
9 May 2019

State of art in systemic management of nmCRPC

Prof Stéphane Oudard - Georges Pompidou Hospital, Paris, France
State of art in systemic management of nmCRPC ( Prof Stéphane Oudard - Georges Pompidou Hospital, Paris, France )
8 May 2019

EAU prostate cancer guidelines 2019: What changed and why?

Prof Nicolas Mottet - University Hospital St Etienne, St Etienne, France
EAU prostate cancer guidelines 2019: What changed and why? ( Prof Nicolas Mottet - University Hospital St Etienne, St Etienne, France )
8 May 2019

Neoadjuvant treatment before radical prostatectomy: Current situation

Prof Nicolas Mottet - University Hospital St Etienne, St Etienne, France
Neoadjuvant treatment before radical prostatectomy: Current situation ( Prof Nicolas Mottet - University Hospital St Etienne, St Etienne, France )
8 May 2019

Emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy vs. oral therapy

Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA
Emerging management of metastatic castration-sensitive prostate cancer: front-line chemotherapy vs. oral therapy ( Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA )
8 May 2019